Skip to main content
SpringerLink
Log in

PDE5-Inhibitoren zur Behandlung des benignen Prostatasyndroms

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Carbone DJ Jr, Hodges S (2003) Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 15: 299–306

    Article  PubMed  Google Scholar 

  2. Chiricos TN, Sanford E (1996) Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 155: 1311–1316

    Article  Google Scholar 

  3. Drescher P, Eckert RE, Madsen PO (1994) Smooth muscle contractility in prostatic hyperplasia: role of cyclic adenosine monophosphate. Prostate 25: 76–80

    Article  PubMed  CAS  Google Scholar 

  4. Guess HA (1995) Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 22: 247–261

    PubMed  CAS  Google Scholar 

  5. Jacobsen SJ, Gues HA, Panser L et al. (1993) A population-based study of health care-seeking behaviour for treatment of urinary symptoms. Arch Fam Med 2: 729–735

    Article  PubMed  CAS  Google Scholar 

  6. McVary KT, Monning W, Camps JL et al. (2007) Sildenafil Citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071–1077

    Article  PubMed  CAS  Google Scholar 

  7. McVary KT, Roehrborn CG, Kaminetsky JC et al. (2007) Tadalafil relieves urinary tract symptoms secondary to Benign Prostatic hyperplasia. J Urol 177: 1401–1407

    Article  PubMed  CAS  Google Scholar 

  8. Rybalkin SD, Yan C, Bornefeldt KE, Beavo JA (2003) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93: 280–291

    Article  PubMed  CAS  Google Scholar 

  9. Soderling SH, Beavon JA (2000) Regulation of cAMP and cGMP signalling: new phosphodiesterases and new function. Curr Opin Cell Biol 12: 174–179

    Article  PubMed  CAS  Google Scholar 

  10. Uckert S, Kuthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166: 2484–2490

    Article  PubMed  CAS  Google Scholar 

  11. Uckert S, Oelke M, Stief CG et al. (2006) Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49: 740–745

    Article  PubMed  Google Scholar 

  12. Wheeler MA, Rajasekhara RA, Wheeler GL, Weiss RM (2005) Regulation of cyclic nucleotides in the urinary tract. J Smooth Muscle Res 41: 1–21

    Article  PubMed  Google Scholar 

Download references

Danksagung

Herzlicher Dank gilt Jörg Hartmann, Jutta Hauenschild, Angelika Rein-Wennmacher, Katja Rheindorf, Karsten Schulte, Kerstin Schultz, Susanne Bendix und Sven Forsthoff für die Durchführung der präklinischen Experimente.

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Angestellter der Bayer Health Care AG.

Author information

Authors and Affiliations

  1. Bayer Health CareAG & Bayer Vital, 42096, Wuppertal, Deutschland

    P. Sandner, H. Tinel, B. Stelte-Ludwig, J. Huetter, D. Neuser, E. Bischoff & E. Ulbrich

Authors
  1. P. Sandner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Tinel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Stelte-Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Huetter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Neuser
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Bischoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Ulbrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Sandner.

Additional information

Bei dieser Arbeit handelt es sich um einen Bericht aus dem Bereich der produktbegleitenden Forschung in Zusammenarbeit mit der klinischen Entwicklung der Bayer Health Care AG sowie in Zusammenarbeit mit Bayer Vital. Die Daten sind teilweise im Br J Urol 2006, 98: 1259–1263 (Tinel et al.), in Endocrinology 2007, 148: 1019–1029 (Filippi et al.) und auf dem Jahreskongress der Amerikanischen Urologischen Gesellschaft (AUA) 2007 (Stief et al.) von den Autoren publiziert worden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sandner, P., Tinel, H., Stelte-Ludwig, B. et al. PDE5-Inhibitoren zur Behandlung des benignen Prostatasyndroms. Urologe 46, 1189–1192 (2007). https://doi.org/10.1007/s00120-007-1478-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-007-1478-3

Search

Navigation